Match!
Ines Vaz-Luis
Harvard University
CancerOncologyChemotherapyBreast cancerMedicine
35Publications
11H-index
472Citations
What is this?
Publications 75
Newest
#1Ines Vaz-Luis (Harvard University)H-Index: 11
#2Romualdo Barroso-Sousa (Harvard University)H-Index: 14
Last. Meredith Gail Faggen (Harvard University)H-Index: 1
view all 21 authors...
PURPOSEThe use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use duri...
Source
#1Arlindo R. Ferreira (IMM: Instituto de Medicina Molecular)H-Index: 8
#2Joana Ribeiro (Champalimaud Foundation)H-Index: 4
Last. I. Vaz-Luís (Institut Gustave Roussy)
view all 10 authors...
Abstract Background Ovarian function suppression (OFS) with tamoxifen or aromatase inhibitors (AIs) improves disease-free survival in premenopausal women with breast cancer, mostly in those at higher risk of recurrence. However, its real-world use and impact remain poorly understood. Patients and Methods This is a multicenter retrospective cohort study of premenopausal women with stage I to III hormone receptor-positive breast cancer diagnosed from 2006 to 2015 that aimed to look at the uptake a...
Source
#1Shoshana M. Rosenberg (Harvard University)H-Index: 15
#2Ines Vaz-LuisH-Index: 11
Last. Ann H. Partridge (Harvard University)H-Index: 57
view all 11 authors...
Purpose Little is known about how a breast cancer diagnosis and treatment affects job-related outcomes in young women with breast cancer, who are an integral part of the workforce. We sought to describe employment trends among young breast cancer survivors.
4 CitationsSource
#1E Martin (Institut Gustave Roussy)
#2A Di Meglio (French Institute of Health and Medical Research)
Last. Ines Vaz-Luis (French Institute of Health and Medical Research)H-Index: 11
view all 10 authors...
Source
#1A R Ferreira (French Institute of Health and Medical Research)
#2A. Paci (French Institute of Health and Medical Research)
Last. Barbara Pistilli (Institut Gustave Roussy)H-Index: 13
view all 10 authors...
Source
#1A. Di Meglio (Institut Gustave Roussy)H-Index: 1
#2Mayssam El-Mouhebb (Institut Gustave Roussy)
Last. I Vaz-Luis (Institut Gustave Roussy)H-Index: 1
view all 18 authors...
Source
#1A. Di Meglio (Institut Gustave Roussy)H-Index: 1
Last. I Vaz-Luis (Institut Gustave Roussy)H-Index: 1
view all 20 authors...
Source
#1Barbara PistilliH-Index: 13
#2Angelo PaciH-Index: 26
Last. I Vaz-Luis (Institut Gustave Roussy)H-Index: 1
view all 20 authors...
4 CitationsSource
#1A. Di Meglio (Institut Gustave Roussy)H-Index: 1
#2Mayssam El-Mouhebb (Institut Gustave Roussy)
Last. I Vaz-Luis (Institut Gustave Roussy)H-Index: 1
view all 20 authors...
Source
#1O MetzgerH-Index: 4
Last. AM DeMicheleH-Index: 6
view all 24 authors...
Background: Pre-clinical data and results from early phase clinical trials point to synergistic antitumor activity and potential efficacy of palbociclib when given in combination with anti-HER2 therapy (tx). The aim of PATINA is to determine the effect of adding palbociclib to anti-HER2 and ET maintenance after induction tx in the 1st line setting for HR+/HER2+ MBC. Trial Design: The PATINA trial (AFT-38/NCT02947685) is a pivotal, open-label, international, phase III study. Following 6-8 cycles ...
3 CitationsSource
12345678